LY-3884963
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for LY-3884963, covering 2026-02-10 to 2026-02-10. Get the full timeline:
Most recent: Clinical Trial Update: Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) [Phase 1, Phase 2]